Tags

Type your tag names separated by a space and hit enter

Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
Int J Infect Dis. 2020 Oct; 99:491-495.IJ

Abstract

INTRODUCTION

No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.

METHODS

We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement.

RESULTS

Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009).

CONCLUSION

Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community.

Authors+Show Affiliations

Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souheil.zayet@hnfc.fr.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Medical Information Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Diabetology and Endocrinology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32798660

Citation

Klopfenstein, Timothée, et al. "Impact of Tocilizumab On Mortality And/or Invasive Mechanical Ventilation Requirement in a Cohort of 206 COVID-19 Patients." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 99, 2020, pp. 491-495.
Klopfenstein T, Zayet S, Lohse A, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020;99:491-495.
Klopfenstein, T., Zayet, S., Lohse, A., Selles, P., Zahra, H., Kadiane-Oussou, N. J., Toko, L., Royer, P. Y., Balblanc, J. C., Gendrin, V., & Conrozier, T. (2020). Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 99, 491-495. https://doi.org/10.1016/j.ijid.2020.08.024
Klopfenstein T, et al. Impact of Tocilizumab On Mortality And/or Invasive Mechanical Ventilation Requirement in a Cohort of 206 COVID-19 Patients. Int J Infect Dis. 2020;99:491-495. PubMed PMID: 32798660.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. AU - Klopfenstein,Timothée, AU - Zayet,Souheil, AU - Lohse,Anne, AU - Selles,Phillippe, AU - Zahra,Hajer, AU - Kadiane-Oussou,N'dri Juliette, AU - Toko,Lynda, AU - Royer,Pierre-Yves, AU - Balblanc,Jean-Charles, AU - Gendrin,Vincent, AU - Conrozier,Thierry, AU - ,, Y1 - 2020/08/13/ PY - 2020/05/30/received PY - 2020/08/07/revised PY - 2020/08/07/accepted PY - 2020/8/18/pubmed PY - 2020/8/18/medline PY - 2020/8/18/entrez KW - COVID-19 KW - Invasive mechanical ventilation KW - Mortality KW - SARS-CoV-2 KW - Tocilizumab SP - 491 EP - 495 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 99 N2 - INTRODUCTION: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. METHODS: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement. RESULTS: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009). CONCLUSION: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community. SN - 1878-3511 UR - https://www.unboundmedicine.com/medline/citation/32798660/Impact_of_tocilizumab_on_mortality_and/or_invasive_mechanical_ventilation_requirement_in_a_cohort_of_206_COVID_19_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(20)30653-6 DB - PRIME DP - Unbound Medicine ER -